Skip to Main content Skip to Navigation
Journal articles

Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.

Abstract : BACKGROUND: Circadian rhythm disruption was linked to high serum levels of Transforming Growth Factor Receptor α, an Epidermal Growth Factor Receptor (EGFR) ligand and poor survival in patients with metastatic colorectal cancer (mCRC). We hypothesized that EGFR blockade with cetuximab would enhance the activity of chronotherapy as a result of improved circadian coordination. METHODS: All the patients with mCRC referred to our unit for progression on prior chemotherapy over a 30-month-period received weekly cetuximab and fortnightly chronotherapy. RESULTS: Fifty-six patients were treated with a median of six courses of fluoropyrimidine-based chemotherapy and irinotecan (61%), oxaliplatin (25%) or both (14%) after a median of three prior regimens. We found no EFGR amplification by FISH in the tumor of 27 consecutive patients. Acneiform rash and diarrhea were the most common toxicities. Objective response rate was 32.1% and positively correlated with rash grade (p = 0.025). None of the responders had K-Ras mutation in their tumor. Median progression-free and overall survival were 4.6 and 13.7 months, respectively. Complete macroscopic resections of metastases in liver, lung or other abdominopelvic sites were performed following tumor downstaging by the treatment regimen in 11 patients (21%), 8 of whom being alive at 3 years. These figures are twice as high as those reported for first-line combination of cetuximab with conventional chemotherapy or for third line chronotherapy. CONCLUSIONS: The addition of cetuximab to chronotherapy allowed safe and effective therapeutic control of metastases, including their complete resection, despite previous failure of several treatment regimens.
Document type :
Journal articles
Complete list of metadatas

Cited literature [9 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00477443
Contributor : Abdoulaye Karaboué <>
Submitted on : Thursday, April 29, 2010 - 11:04:10 AM
Last modification on : Wednesday, October 14, 2020 - 3:45:25 AM
Long-term archiving on: : Wednesday, November 30, 2016 - 5:36:39 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Francis Lévi, Abdoulaye Karaboué, Lee Gorden, Pasquale Fabio Innominato, Raphael Saffroy, et al.. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.. Cancer Chemotherapy and Pharmacology, Springer Verlag, 2011, 67 (2), pp.339-48. ⟨10.1007/s00280-010-1327-8⟩. ⟨inserm-00477443⟩

Share

Metrics

Record views

347